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Background: The development of chemical refolding of transforming growth factor-beta (TGF-β) superfamily
ligands has been instrumental to produce the recombinant proteins for biochemical studies and exploring the
potential of protein therapeutics. The osteogenic human bone morphogenetic protein-2 (hBMP-2) and its Drosophila
DPP homolog were the early successful cases of refolding into functional form. Despite the similarity in their three
dimensional structure and amino acid sequences, several other TGF-β superfamily ligands could not be refolded readily
by the same methods.
Results: Here, we report a comprehensive study on the variables of a rapid-dilution refolding method, including the
concentrations of protein, salt, detergent and redox agents, pH, refolding duration and the presence of aggregation
suppressors and host-cell contaminants, in order to identify the optimal condition to refold human BMP-9 (hBMP-9). To
produce a recombinant form of hBMP-9 in E. coli cells, a synthetic codon-optimized gene was designed to encode the
mature domain of hBMP-9 (Ser320 – Arg429) directly behind the first methionine, which we herein referred to as
MB109. An effective purification scheme was also developed to purify the refolded MB109 to homogeneity with a final
yield of 7.8 mg from 100 mg of chromatography-purified inclusion bodies as a starting material. The chemically
refolded MB109 binds to ALK1, ActRIIb and BMPRII receptors with relatively high affinity as compared to other Type I
and Type II receptors based on surface plasmon resonance analysis. Smad1-dependent luciferase assay in C2C12 cells
shows that the MB109 has an EC50 of 0.61 ng/mL (25 pM), which is nearly the same as hBMP-9.
Conclusion: MB109 is prone to be refolded as non-functional dimer and higher order multimers in most of the
conditions tested, but bioactive MB109 dimer can be refolded with high efficiency in a narrow window, which is
strongly dependent on the pH, refolding duration, the presence of aggregation suppressors and the concentrations of
protein, salt and detegent. These results add to the current understanding of producing recombinant TGF-β superfamily
ligands in the microbial E. coli system. An application of the technique to produce a large number of synthetic TGF-β
chimeras for activity screen is also discussed.
Keywords: TGF-beta, BMP-9, MB109, Refolding, Rapid dilution, E. coli, Recombinant cytokine* Correspondence: mariokuo.jcb@gmail.com; senyon.choe2@gmail.com
1Protein Engineering Laboratory, joint Center for Biosciences, Songdo Smart
Valley, 214 Sondgo-dong, Yeonsu-gu, Incheon 406-840, Korea
2Drug Discovery Collaboratory, Carlsbad Center for Translational Medicine,
Carlsbad, CA 92008, USA
© 2014 Kuo et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Kuo et al. Microbial Cell Factories 2014, 13:29 Page 2 of 13
http://www.microbialcellfactories.com/content/13/1/29Background
Bone morphogenetic proteins (BMPs) are extracellular
growth factors that belong to the transforming growth
factor-beta (TGF-β) superfamily. Among the seventeen
members in the BMP subfamily, BMP-9 is distinguished
from other BMPs by its unique receptor-binding specificity
and its diverse roles in a variety of cellular processes. For
example, BMP-9, as well as BMP-10, signals only through
the activin receptor-like kinase 1 (ALK1) to trigger down-
stream cellular responses, while the other BMP ligands
interact promiscuously with multiple, different type I re-
ceptors [1-3]. BMP-9 can induce apoptosis in prostate can-
cer cells [4], promote the proliferation of ovarian cancer
cells [5] and stimulate epithelia to mesenchymal transition
in liver cancer cells [6]. It regulates the growth and migra-
tion of endothelial cells, thus also playing an essential role
in angiogenesis [7,8]. BMP-9 is one of the most potent
BMPs to induce osteogenic differentiation and orthotopic
bone formation [9,10]. It also promotes chondrogenic dif-
ferentiation in cultured multipotential mesenchymal cells
and articular chondrocytes [11,12]. Due to these character-
istics, BMP-9 has been suggested as an effective bone re-
generation and tissue repair agent for clinical applications
[13]. In addition to angiogenesis, osteogenesis and chon-
drogenesis, BMP-9 is also a potent inducer of the choliner-
gic phenotype in the central nervous system, and thus has
the potential to be used in regenerative medicine to treat
disease related to cholinergic neurons [14]. BMP-9 is add-
itionally able to inhibit the production of hepatic glucose
and to activate the expression of several key enzymes in
lipid metabolism [15], which makes it a potential candidate
for diabetes treatment and weight control.
Because of the diverse biological functions and pharma-
ceutical potentials, there is significant interest in the
production of recombinant human BMP-9 (hBMP-9). A
full-length hBMP-9 polypeptide contains 429 amino
acid residues, including an amino-terminal signal pep-
tide, a pro-region and a carboxyl-terminal mature do-
main. The bioactive hBMP-9 ligand is a disulfide-linked
homodimer of the mature domain, from Ser320 to Arg429
(110 amino acids). Each polypeptide chain of the homodi-
mer has seven cysteine residues, which form three intra-
molecular and one inter-molecular disulfide bonds. As re-
vealed in the X-ray structure, these seven disulfide bonds
constitute the characteristic cystine knot and common
structural scaffold of the TGF-β superfamily ligands [1].
Because of the complexity of this disulfide-linked molecule,
production of sufficient amount of recombinant hBMP-9
ligand for research purposes had only been achieved with
mammalian Chinese hamster ovary (CHO) cells [1,3,15].
The CHO cell expression system utilizes the innate mam-
malian cellular machinery to fold the molecule and form
the disulfide bonds. After post-translational modifications,
bioactive hBMP-9 is secreted into the conditioned mediumand can be purified with chromatographic methods [16].
The CHO-derived hBMP-9 mature domain has a molecu-
lar weight close to its theoretic value on SDS-PAGE, which
indicates that it is not glycosylated [1,15,16].
Although the CHO expression system allows the produc-
tion and purification of sub-milligram to milligram quan-
tities of bioactive BMPs directly from a liter of conditioned
medium [17], it is costly and time consuming to establish a
high-expressing, stable cell line. This disadvantage be-
comes a major technical barrier when tens or hundreds of
chimera TGF-β ligands need to be generated simultan-
eously for activity screens [18]. Alternatively, a microbial
system using E. coli cells has been developed to produce
recombinant TGF-β superfamily ligands in a simple and
economical manner. The osteogenic human bone mor-
phogenetic protein-2 (hBMP-2) and its Drosophila DPP
homolog were the early successful cases [19,20]. When
overexpressed in E. coli cells, the mature domains of
hBMP-2 and Drosophila DPP form water-insoluble in-
clusion bodies and require in vitro denaturation and re-
naturation to form their native protein conformations
[19-22]. Common refolding variables and parameters
derived from these early studies have been used as stand-
ard refolding conditions to successfully produce other
BMP ligands, such as hBMP-3, hBMP-6, hBMP-2/6 het-
erodimer, hBMP-12, hBMP-13 and activin-BMP-2 chi-
meras with a yield sufficient for structural and functional
studies [18,23-25]. However, the standard refolding condi-
tions that work for the mentioned ligands are not gener-
ally applicable to refold other TGF-β superfamily ligands,
even though these ligands share a common structural
scaffold [18]. The exact reasons remain elusive for why
the standard refolding conditions can only refold a limited
numbers of TGF-β superfamily ligands.
In this study, we used E. coli cells as an expression host
and created a synthetic, codon-optimized gene that en-
codes the mature domain of hBMP-9 (Ser320 – Arg429)
directly behind a Met start codon, which we herein refer
to as MB109. We did a comprehensive analysis of several
variables to the standard refolding conditions to identify
and optimize the critical variables and parameters to re-
fold bioactive MB109 with high efficiency. An effective
purification scheme was also developed to purify the
refolded MB109 to homogeneity. Finally, the biological ac-
tivity was confirmed by Smad1-dependent luciferase re-
porter assay and receptor-binding specificity performed
with surface plasmon resonance analysis with immobilized
extracellular domains of Type I and Type II receptors.
Results
Expression and purification of denatured, monomeric
MB109
To express the mature domain of hBMP-9, a synthetic,
codon-optimized gene, encoding Ser320–Arg429 of NCBI
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promoter (Figure 1A). This recombinant gene product,
which we refer to as MB109, contains Met as the N-
terminus followed by the coding region of the mature do-
main of hBMP9. The expression plasmid was transformed
into BL21 E. coli cells and the transformants were cultured
in LB-broth under aerobic condition in a shaking incubator.
After IPTG induction for 20 hours at 37°C, the cells wereFigure 1 Expression of MB109 in E. coli cells and purification of the is
polypeptide expressed in this study. The first methionine (bold) is engineer
residues are highlighted in gray. (B) Reduced SDS-PAGE gel of the expresse
IPTG induction, respectively. Lane 4 and 5 are supernatant and pellet, respe
bodies. The black arrow indicates the monomeric MB109 protein. (C) Size e
panel) and Superdex 75 16/60 (right-upper panel) loaded with the isolated
each corresponding elution fractions. Gray bars highlight the fractions cont
MB109 protein.lysed by microfluidization and the expression of the target
protein was analyzed by SDS-PAGE. In the whole cell lys-
ate, MB109 was present in the non-soluble fraction and
could be isolated by centrifugation, indicating the formation
of inclusion bodies (Figure 1B, lane 5). About 150 mg in-
clusion bodies were isolated from one liter of cell culture.
After washing three times, the inclusion bodies remained
associated with some contaminant proteins (Figure 1B,olated inclusion bodies. (A) Amino acid sequence of the MB109
ed to serve as translational start. The seven conserved cysteine
d MB109 protein. Lane 2 and 3 are whole cell lysates before and after
ctively, of the IPTG-induced cell lysate. Lane 6 is isolated inclusion
xclusion chromatographic profiles of Superdex 200 16/60 (left-upper
inclusion bodies. Bottom panels are reduced SDS-PAGE gel images of
aining MB109 monomers. The black arrows indicate the monomeric
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tein prior to refolding screen, the isolated inclusion bodies
were solubilized in reduced and denatured condition and
subjected to chromatographic purification by size exclu-
sion chromatography (SEC) using a HiLoad Superdex™ 75
or 200 column (GE Healthcare). We found that even
though these two types of gel filtration columns have dif-
ferent separation ranges of molecular size, they gave simi-
lar results in terms of final purity and yield of the
denatured monomeric MB109 protein. In the Superdex™
200 column, the solubilized inclusion bodies were eluted
as three major peaks at around 46, 72 and 83 mL, with the
target MB109 protein present in the last peak (Figure 1C,
gray bar). In the Superdex™ 75 column, the solubilized in-
clusion bodies were eluted as two, well-separated peaks,
with the target MB109 protein present in the second peak
(Figure 2D, gray bar). The fractions containing the mono-
meric MB109 protein were pooled and concentrated to
20 mg/mL for refolding. About 50 mg of monomeric
MB109 was purified from 100 mg of solubilized inclusion
bodies using either column.
Effect of salt concentration on the refolding of MB109
The standard refolding conditions, derived from early
studies to readily refold DPP and other BMPs, contain a
minimal set of six components: detergent (CHAPS), salt
(NaCl), chelator (EDTA), redox agents (reduced and oxi-
dized glutathiones, GSH and GSSG, respectively) and
buffer (Tris-HCl) [18,20,23-26]. To determine which var-
iables are critical for refolding MB109, we first varied
the NaCl concentration from 0 to 4 M and fixed the
other refolding variables at their commonly used values
(Figure 2A, middle panel). After 7 days incubation at 4°C,
visible aggregates were spun down and the supernatants
were concentrated to directly visualize the refolding re-
sults in non-reduced SDS-PAGE. In the absence of NaCl,
most protein aggregated in the refolding solution and thus
limited protein remained in the supernatant after centrifu-
gation (Figure 2A, top panel, lane 1). In the presence of
NaCl, MB109 refolded into monomer, dimer and higher
order multimers (Figure 2A, top panel, lanes 2-6).
In the top panel of Figure 2A, there are two well-
separated bands in Lanes 2-6 at around 20–30 kDa,
which have a size close to the theoretic molecular weight
of dimeric MB109 (24.4 kDa). The protein of the bottom
band (black arrow) was purified and its bioactivity was
subsequently confirmed (see below). We refer to it as
“functional dimer” and we used it as a reference of cor-
rectly refolded MB109 on SDS-PAGE. The upper band
(gray arrow), which is not bioactive after being purified
(see below), is referred to as “chemical dimer.” The
densitometry of the functional dimer bands in the SDS-
PAGE image (Figure 2A, bottom panel) revealed that the
optimal refolding salt concentration for MB109 wasaround 1.0–2.0 M. At salt concentrations increasingly
above 2 M, the refolding efficiency was reduced gradually.
Effect of pH on the refolding of MB109
To analyze the pH effect on refolding MB109, the salt
concentration was fixed at 2 M and the buffer pH was
varied between 7.0 and 10.0 at a 0.5 interval. As shown
in the upper panel of Figure 2B, the functional dimer
band was only observed between pH 7.5 and 9.5 (lanes
2-6). The chemical dimer, as well as monomer and mul-
timer, were present in all tested pH conditions (lanes 1-7).
The refolding efficiency of the functional dimer had sharp
pH dependency. The optimal refolding pH was found to
be between 8.0 and 8.5, and the refolding efficiency re-
duced drastically outside of this range (Figure 2B, bottom
panel).
Effect of detergent concentration on the refolding of
MB109
In the standard refolding conditions, 1.8–2% CHAPS had
been used to refold DPP and other BMPs [18,20,23-26].
To test the effect of CHAPS concentration on refolding
MB109, 0 to 4% CHAPS was used in the refolding solu-
tion. In the absence of the detergent, MB109 formed vis-
ible aggregates in the refolding solution after 7 days of
incubation, and thus little protein remained in the super-
natant after centrifugation (Figure 2C, top panel, lane 1).
At a CHAPS concentration above 0.5%, the functional
dimer could be refolded; the refolding efficiency was posi-
tively correlated with the amount of CHAPS in the refold-
ing solution (Figure 2C, bottom panel). When compared
to the commonly used 2% CHAPS concentration, the
yield of the functional dimer increased about 37% and
58% in the presence of 3% and 4% CHAPS, respectively.
Effect of redox condition on the refolding of MB109
Because a bioactive BMP molecule contains several di-
sulfide bonds, reduced and oxidized glutathiones (GSH
and GSSG, respectively) had been used as a redox sys-
tem in refolding solution to allow the formation and
reshuffling of disulfide bonds. To identify the optimal
redox condition, millimolar ratios between 10:1 and 1:10
of GSH and GSSG were tested (Figure 2D). Interestingly,
the refolding efficiency of the functional dimer depended
mostly upon the amount of GSSG, but not GSH, in the
refolding solution. In other words, the more oxidizing
“power” (GSSG) in the solution, the functional dimer
was refolded less efficiently (Figure 2D, conditions 4-7).
In contrast, increasing the reducing “power” (GSH) in
the refolding solution did not significantly affect the
refolding efficiency (Figure 2D, conditions 1-4). The
maximal refolding efficiency was observed at the com-
bination of 2 mM GSH and 1 mM GSSG.
Figure 2 (See legend on next page.)
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Figure 2 Analysis of refolding variables to identify the optimal refolding conditions for MB109. (A) Top panel is non-reduced SDS-PAGE
gel image showing the result of refolding in 0–4 M NaCl. Black and gray arrows indicate the refolded functional and chemical dimers, respectively.
Middle panel shows the detail of each refolding condition. Bottom panel is densitometry of the functional dimer bands in the top SDS-PAGE
image. The data show relative refolding yield in each tested condition as compared to the highest one (set as 100%). (B-F) Refolding of MB109 at
pH 7–10 (B), in 0–4% CHAPS detergent (C), in different molar ratios of reduced (GSH) and oxidized (GSSG) glutathiones (D), at 0.05–0.4 mg/mL
protein concentrations (E), and the time course of MB109 Refolding at 4°C (F). (G) Effect of secondary additives on the refolding of MB109. The
background conditions were 1.5 mM NaCl, pH 8.3, 2% CHAPS, 1/1 mM GSH/GSSG, 0.2 mg/mL protein, 2 mM EDTA and 4°C for 7 days.
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In all of the refolding conditions tested above, a chem-
ical dimer and higher order multimers of MB109 were
prone to form over the functional dimer. This result
suggests that the protein concentration (0.2 mg/mL)
used for the refolding tests may be too high to form the
functional dimer and instead cause the non-specific multi-
merization observed. To understand the effect of protein
concentration on the refolding yield, protein concentra-
tions between 0.05 and 0.4 mg/mL were tested (Figure 2E).
Indeed, the refolding yield was reversely correlated with
the protein concentration in the refolding solution. At
0.05 mg/mL, the tendency to form higher order multimers
was significantly reduced (Figure 2E, top panel, lane 1),
and the yield of the functional dimer increased about 55%
as compared to the solution refolded at 0.2 mg/mL (bot-
tom panel).
Effect of refolding duration on the refolding of MB109
In addition to the chemical variables tested above, the
refolding time course was analyzed for up to 11 days at
4°C to identify the time required to achieve maximal
refolding yield. As shown in Figure 2F, the functional
dimer band could be seen to after 2 days and the yield
plateaued after 9 days of incubation.
Effect of secondary additive on the refolding of MB109
Some chemical additives are known to be effective aids for
in vitro protein refolding [27,28]. To determine whether
the refolding yield could be further improved, we tested
the commonly used aggregation suppressors and denatur-
ants, including L-arginine, L-proline, glycerol, urea, and
guanidine. As shown in Figure 2G, addition of 0.5 M L-ar-
ginine, 0.5 M L-proline, 1.5 M urea, and 1 M guanidine
significantly reduced the efficiency of refolding the func-
tional dimer, whereas the addition of 10% glycerol pro-
vided a minimal increase on the refolding yield.
Effect of host cell contaminants on the refolding of
MB109
As shown in the lane 6 of Figure 1B, the isolated inclu-
sion bodies of MB109 contain a visible amount of host
cell contaminants on SDS-PAGE. Although these con-
taminants could be effectively removed by size exclusion
chromatography prior to refolding, it would be cost-effective if this purification step were omitted. Therefore,
the refolding efficiency was tested in the presence of the
host cell contaminants by using the isolated inclusion
bodies in the refolding conditions outlined above (vari-
ation of pH and salt and CHAPS concentrations). As
shown in the upper panels of Figure 3, the functional
dimer (black arrows) was refolded in the presence of
host cell contaminants. Similar to the size-exclusion
purified inclusion bodies, the non-purified inclusion
bodies were refolded into functional dimer with an opti-
mal pH of 8.0–8.5 (Figure 3A), an optimal NaCl concen-
tration of 1–2 M (Figure 3B), and a positive correlation
with increasing CHAPS detergent concentration, plat-
eauing around 3% (Figure 3C).
Purification of the refolded MB109
In all of the refolding conditions analyzed above, the dena-
tured MB109 was refolded into not only the functional
dimer, but also other variants, including the chemical
dimer, monomer and multimer (Figure 2). These variants
were considered as contaminants because of their lack of
bioactivity, and thus we attempted to separate the variants.
To separate the functional dimer from the contaminants,
we found that the majority of the contaminants could be
effectively separated by precipitation when the pH of the
refolding mixture was directly titrated to 3.2. As shown in
Figure 4A, the majority of contaminants formed water in-
soluble aggregates at pH 4.2 and 3.2 and could be re-
moved by centrifugation (lanes 4 and 6, respectively),
while the functional dimer remained in the supernatant
(lane 3 and 5). At pH 2.2, however, the functional
dimer started to form water insoluble aggregates as well
(Figure 4A lane 8, black arrow).
After acidic fractionation, small amounts of chemical
dimer, monomer and multimer remained in the super-
natant (Figure 4A lane 5). To further purify the functional
dimer, size exclusion chromatography with Superdex 75
and Superdex 200 connected in series was used. As shown
in Figure 4B, the multimer and chemical dimer were
eluted at 113–128 mL, before the function dimer was
eluted at 128–137 mL (gray box). However, some of the
monomeric variants were co-eluted with the functional
dimer (Figure 4B, bottom panel, lane 6–8).
To remove the remaining monomeric variants, SP
Sepharose Fast Flow cation exchange was found to be
Figure 3 Effect of host cell contaminants on the refolding of MB109. Isolated inclusion bodies, without SEC purification, were directly used
to set up the refolding at 0.2 mg/mL. Black arrows indicate the refolded functional dimer. (A) Refolding at pH 7–10. The densitometry of the
functional band in each condition is shown in black squares and lines. Gray squares and lines are the refolding results from Figure 2 for
comparison. (B and C) Refolding in 0–4 M NaCl (B) and 0–4% CHAPS (C).
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monomeric contaminants were washed out around
10.5 mS/cm and the functional dimer was eluted around
13.4 mS/cm. After this step, the purity of the purified
functional dimer was greater than 95%, as determined by
non-reduced and reduced SDS-PAGE (Figure 4D). The
final yield of the purified MB109 was 7.8 mg per 100 mg
of SEC purified inclusion bodies under the optimal refold-
ing conditions.
Bioactivity of refolded MB109
The bioactivity of the purified MB109 was first tested by
examining its ability to stimulate the Smad1 signaling
pathway in an established Smad1-dependent luciferase re-
porter system in mouse myoblast C2C12 cells (Figure 5A).
A CHO-derived hBMP-9 and an E. coli-derived hBMP-2
were used as positive controls. As shown in Figure 5A,the purified MB109 was able to induce dose-dependent
Smad1 signaling response with an EC50 of 0.61 ng/mL
(25 pM, black circles), which was similar to that induced
by CHO-derived hBMP-9 (EC50 of 0.92 ng/mL, 38 pM,
gray circles). This is about a 43-fold higher response
than that induced by E. coli-derived hBMP-2 (EC50 of
28.1 ng/mL, 1.08 nM, black squares).
To determine receptor binding specificity, purified
MB109 was subjected to surface plasmon resonance
analysis to determine its binding affinities to immobi-
lized extracellular domains (ECDs) of Type I and Type II
receptors, including ALK1, ActRIa (ALK2), ActRIb (ALK4),
BMPRIa (ALK3), BMPRIb (ALK6), TGFβRI (ALK5), ALK7,
ActRIIa, ActRIIb, BMPRII, TGF-βRII and MISRII. Among
these receptor ECDs, MB109 had strong binding affinity
only to ALK1, ActRIIb and BMPRII, while the binding to
the other receptor ECDs were either very transient (to
ActRIIa) or non-detectable (Figure 5B).
Figure 4 Purification of the refolded MB109 functional dimer. (A) Upper panel is a non-reduced SDS-PAGE image showing the aggregation
property of the refolded MB109 proteins at pH 5.2, 4.2, 3.2 and 2.2. Black arrow indicates the functional dimer. S: supernatant; P: pellet. Bottom
panel is the corresponding densitometry of the functional dimer band in each lane. Black and gray bars represent the relative amounts of
functional dimer in supernatants and pellet, respectively. (B) Upper panel, size exclusion chromatographic profile of Superdex 75 and 200 16/60
(connected in series) loaded with acidic fractionated supernatant. Gray bar highlights the fractions pooled for next purification step. Bottom panel
is non-reduced SDS-PAGE gel image of each corresponding elution fractions. (C) Ion exchange chromatographic profile of HiTrap SP-FF (1 mL)
loaded with the size-exclusion purified sample. Solid line, absorption of 280 nm; dashed line, conductance. Gray bar highlights the fractions
containing the functional dimer. (D) Purity analysis of the purified functional dimer on reduced and non-reduced SDS-PAGE gel. The protein was
loaded at 0.5, 1, 2, and 10 μg in the absence (left) or presence (right) of 100 mM DTT.
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The E. coli expression system, in combination with a
protein refolding technique, is a simple, straightforward,
and cost-effective method to produce recombinant TGF-
β superfamily ligands. This method takes the advantages
of well-established molecular tools and robust protein
expression capability of the E. coli cells. As compared to
the CHO cell expression system, this procedure is par-
ticularly suitable to generate a large number of synthetic
TGF-β chimeras [18], without the time consuming steps
of establishing stably transfected cell lines and screening
for individual high expression clones. The E. coli expres-
sion and refolding method can also be directly incorpo-
rated into a mid- or high-throughput activity screen
platform to identify novel biologics, similar to the anti-
body discovery platform [29]. Although many studies on
refolding technology exist in the literature, the methods
developed for TGF-β superfamily ligands have been
mostly limited to BMP-2 and activin A [20-22,30,31].However, the standard conditions derived from these
early studies were not generally applicable to effectively
refold other TGF-β superfamily ligands. To overcome
this bottleneck step, we performed a comprehensive study
on several refolding variables to investigate how each
individual refolding variable affects the overall refolding
efficiency of BMP-9, which has significant therapeutic
interest.
We found that the optimal refolding of MB109 took
more than 7 days at 4°C, which is relatively slow com-
pared to the Drosophila DPP, hBMP-2 and activin A (3-
7 days) [20,30,31]. The refolding efficiency was strongly
dependent on pH and the concentrations of NaCl,
CHAPS and protein in the refolding solution. The pres-
ence of several commonly used denaturants and aggre-
gation suppressors (secondary additives), especially
guanidine, had detrimental effect on MB109 refolding.
Guanidine was found previously to be advantageous in
the refolding of hBMP-2 [22]. The combination of all
Figure 5 Activity assays of the purified MB109. (A) Smad1-depend
luciferase reporter assay in mouse myoblast C2C12 cells. Black circles
are E. coli-derived MB109. Gray circles are CHO-derived hBMP-9. Black
squares are E. Coli-derived hBMP-2. S.E.M. are shown, n = 3. (B) Binding
affinities of MB109 to Type I and Type II receptors as determined by
surface plasma resonance. ECD-Fc, extracellular domain with C-terminal
human IgG1 tag. ND, non-detectable (no signal above the background
detection was detected in all tested protein concentration ranging
from 20 to 0.3 nM).
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MB109 to be refolded with high efficiency. In other
words, this narrow window could be easily missed in a
refolding screen specially if several variables are varied
at the same time or extreme screening conditions are
used. The only variable that allowed for refolding in a
wide range of conditions was the redox condition. As
long as the amount of reducing agent (GSH) was equal
to or more than the oxidizing agent (GSSG), MB109
could be refolded with similar efficiency.
Overall, several optimal refolding parameters we iden-
tified for MB109 are similar to those conditions used to
refold Drosophila DPP, hBMP-2, 3, 6, 2/6, 12 and 13
[20,22-26]. This may suggest a common kinetic refolding
mechanism of the BMP family ligands [31]. Therefore,
perhaps all of the BMP family ligands can be refolded by
the common set of chemical components and variables
discussed here, only with some variations in theiroptimal ranges. This concept is particularly valuable for
designing a high-throughput refolding platform to refold
tens or hundreds of synthetic TGF-β chimeras at the
same time. For example, the common set of chemical
components and variables could be used in a first-round
refolding screen to identify commonly refoldable ligands.
Then, other variables, such as detergent, pH, salt or sec-
ondary additives, could be varied individually in subse-
quent screens to find additional refoldable ligands. In
addition to the refolding variables, we also showed that
the presence of host cell contaminants has no detrimen-
tal effect on refolding MB109. A similar result was also
observed from a hBMP-2 study [22]. These results sug-
gest that the refolding mechanism of the TGF-β super-
family ligands is fairly robust, such that the denatured
polypeptide can effectively form proper disulfide-bonds
and dimerize with high efficiency, allowing for a large
number of synthetic TGF-β chimera to be refolded in a
high-throughput manner without prior chromatographic
purification of the inclusion bodies.
It has been shown that different detergents can be used
to refold activin A to varied degrees of efficiency, among
which TDCA (sodium taurodeoxycholate) was identified
to be the most effective [30]. The detergent-like CHES
[2-(cyclohexylamino)ethanesulfonic acid] has also been
used to refold hBMP-2 [21,22,31] and, as stated above, the
CHAPS detergent has been used to refold Drosophila
DPP, hBMP-2, 3, 6, 2/6, 12 and 13 [20,23-26]. These
results indicate that detergent is an indispensable
additive to refold TGF-β superfamily ligands; however,
the optimal detergent may not be the same for each
member, thus necessitating an additional detergent screen.
Because the presence of CHAPS allowed for the ability to
refold MB109, an additional detergent screen was not
performed in this study.
In the purification step, a first attempt had been made
to develop a procedure at alkaline pH, as described for
Drosophila DPP purification [20]. However, the refolded
MB109 functional dimer was found to be unstable dur-
ing the purification process at alkaline pH, presumably
due to errors in disulfide bond formation. Because disul-
fide shuffling can be effectively prevented in acidic con-
ditions, the first step in the purification procedure was
designed to address this by directly titrating down the
pH of the refolded sample. Interestingly, at acidic pH
the refolded functional dimer remained stable, while a
majority of other refolded variants (chemical dimer,
monomer and multimer) were unstable and formed ag-
gregates (Figure 4A). This biochemical property appears
to be common among the TGF-β superfamily ligands,
because the refolded variants of hBMP-2 and some of
the activin-BMP-2 chimeras [18] can also be precipitated
by the same titration method after the refolding step
(unpublished observations). After the acidic titration
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multimer remained (Figure 4A).
To further remove the remaining contaminants, we
tested several cation exchange media, such as SP Sephar-
ose Fast Flow, SP Sepharose XL, SP Sepharose High Per-
formance and CM Sepharose Fast Flow (GE Healthcare),
but none were able to separate the target from the con-
taminants in a single chromatographic step. This problem
may be due to the fact that the remaining contaminants
are chemical dimer, monomer and multimer variants,
which have the same amino acid sequence as the func-
tional dimer. The core of each subunit of the functional
dimer contains three disulfide bonds, all with nearly the
same bonding distances. Because the remaining contami-
nants have the same amino acid sequence and isoelec-
tronic point, the contaminants may only differ from
the functional dimer in the pattern of the formation of
these three disulfide bonds, resulting in alternate local
conformations.
Due to the lack of success with the cation exchange
media to remove the small amount of contaminants after
the acidic titration step, we attempted size-exclusion chro-
matography and found that we were able to separate a
portion of the monomeric variants and all of the chemical
dimer and multimer from the functional dimer (Figure 4B).
The remaining monomeric variants could be subsequently
removed effectively with an additional step of cation ex-
change chromatography. Therefore, the entire purification
procedure consisted of two chromatographic steps (size
exclusion chromatography followed by cation exchange
chromatography). This purification procedure was devel-
oped with general applicability in mind, so that it could be
applied to purify other TGF-β superfamily ligands as well
as synthetic TGF-β superfamily chimeras. Indeed, we
found that hBMP-2 and some of the activin-BMP-2 chi-
meras [18] could be effectively purified by this procedure
with minor differences in their chromatographic profiles
(unpublished observations). Additionally, when the non-
purified inclusion bodies were refolded directly, the host
cell contaminants present in the refolded MB109 were re-
moved effectively with the same purification procedure.
Our luciferase reporter assay demonstrated that
MB109 is equal to the CHO-derived hBMP-9 in terms
of Smad1 signaling capability. The receptor binding
analysis by surface plasmon resonance also showed that
the E. coli-derived MB109 binds specifically to the
ALK1 Type I receptor and to the ActRIIb and BMPRII
Type II receptors. The receptor binding results are con-
sistent with recent data using CHO-derived hBMP-9
[3]. More recently, we have shown that MB109 en-
hances brown adipogenesis in human adipose tissue-
derived stem cells in vitro and suppresses weight gain-
ing in high fat diet-induced obese mice in vivo [32]. Our
activity data demonstrate that the E. coli-derivedMB109 has the equal quality and potentials in clinical
applications as CHO-derived hBMP-9.
To improve the yield in the E. coli expression system
and to optimize the refolding platform for large-scale
production, several steps in the overall procedure can be
further optimized. For example, continuous or pulse
refolding, instead of rapid-dilution refolding, may im-
prove the refolding yield, as in the case of hBMP-2 [22].
The cell density of the cell culture, as well as the protein
expression, can be obviously improved by using a bio-
reactor and alternate induction methods over a shaking
flask and IPTG induction at 37°C [21], including pos-
sible production of nonclassical inclusion bodies, which
may bypass the lengthy refolding procedures [33,34]. To
simplify the purification step, an affinity column made
with the ECDs of the ALK1, ActRIIb or BMPRII recep-
tor may be used to directly capture the MB109 func-
tional dimer after the refolding step to purify the protein
in a single chromatographic step. The cost effectiveness
of any of these proposed procedures would have to be
evaluated.
Conclusions
This study revealed a simple, straightforward, and cost-
effective technique to produce bioactive human BMP-9,
as an E. coli-derived recombinant protein MB109. Be-
cause BMP-9 had never been refolded successfully, and
could previously only be produced from the more ex-
pensive CHO cell system, MB109 can now be used not
only to facilitate BMP-9 related biomedical research, but
can also be scaled-up for industrial production. In
addition, this study identified the critical variables to re-
fold human BMP-9 with high efficiency. The optimal
refolding parameters can serve as a basis for further
optimization of the refolding yield utilizing alternate
refolding techniques. In conclusion, these findings add
to the current understanding of how to improve the
refolding efficiency of TGF-β superfamily ligands. This is
particularly valuable when a synthetic TGF-β superfam-
ily library, containing tens or hundreds of chimeras,
could to be produced simultaneously for a rapid activity
screen.
Methods
Molecular biology and E. coli cell culture
The gene of the mature domain of human BMP-9
(Ser320 – Arg429), containing a 5′ start codon and a 3′
stop codon, was synthesized by Genscript (NJ, USA).
The codon usage was optimized for maximal E. coli ex-
pression. The synthetic gene was ligated into a pET21a
vector (Novagen, USA) between the NdeI and XhoI re-
striction enzyme sites to make the expression plasmid.
The sequence was confirmed by DNA sequencing after
cloning.
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into BL21 E. coli cells by heat shock. The transformants
were selected on an LB-broth agar plate, containing
100 μg/mL ampicillin (LBamp). A single colony was in-
oculated in 10 mL LBamp medium and incubated aerob-
ically at 37°C for 16 hours. The overnight culture was
diluted 200-fold into 1 L fresh LBamp medium and in-
cubated aerobically in a shaking incubator at 37°C.
When the cell density reached OD600 ~0.4, 0.5 mM
IPTG (isopropyl β-D-1-thiogalactopyranoside) was added
into the cell culture to induce the protein expression.
After 20 hours of expression at 37°C, the cells were har-
vested by centrifugation.
Inclusion body isolation and chromatographic purification
of denatured MB109
To isolate inclusion bodies, the cells were resuspended
in deionized water in the presence of 1 mM phenyl-
methylsulfonyl fluoride (PMSF) and lysed by passing
through a Nano DeBEE microfluidizer. The inclusion
bodies in the cell lysate were precipitated by centrifuga-
tion, and washed three times by repeated resuspension
and centrifugation. The washed inclusion bodies were
dissolved in an 8 M urea buffer solution in the presence
of dithiothreitol (DTT) and stored at -80°C to be used
for setting up refolding directly or for further chromato-
graphic purification.
The gel filtration chromatography was performed with
an Akta Prime plus FPLC. HiLoad 16/60 Superdex™ 75
and 200 columns (GE Healthcare) were used to elute the
protein. The fractions containing monomeric MB109
were pooled, concentrated by Vivaspin20 concentrators
(Sartorius AG, Germany) and stored at -80°C to be later
used for refolding. The protein concentration was deter-
mined by using the Bio-Rad Protein Assay Kit (Bio-Rad
Laboratories, USA).
Chemical refolding and purification of refolded MB109
The small-scale refolding screen analyses were performed
with a final volume of 1–5 mL. For rapid dilution, the
purified monomeric MB109 was diluted directly into cold
refolding solutions, mixed rapidly by vortexing and incu-
bated at 4°C. To visualize the progress of refolding, visible
protein aggregates in the sample solutions were spun
down first and the supernatants were diluted in an acidic
buffer solution to stop disulfide reshuffling or redox reac-
tion and concentrated to run on non-reduced 12% SDS-
PAGE. The densitometry of the functional dimer bands
on the SDS-PAGE gel images was analyzed by using the
GeneTools image analysis software (Synoptics, UK). To
purify the refolded MB109 functional dimer, the pH of the
refolded sample was titrated directly to 3.2 and subjected
to gel filtration chromatography by HiLoad 16/60 Super-
dex™ 75 and 200 columns (Figure 4B). For cation exchangechromatography, 1-mL HiTrap SP Sepharose Fast Flow
column (GE Healthcare) was used with the elution salt
gradient ranging from 0 to 1 M NaCl (Figure 4C).
Smad1-dependent luciferase reporter assay
C2C12 cells were purchased from American Type Culture
Collection and were cultured in Dulbecco’s modified ea-
gle’s medium (DMEM) containing 100 U/mL penicillin,
0.1 μM streptomycin and 10% FBS. The cells were incu-
bated at 37°C under a humidified condition of 5% CO2
and routinely subcultured using trypsine-EDTA when the
cell density reached around 80% confluence. Smad1-
dependent luciferase report assays were performed as pre-
viously described [18,24,35]. In short, cultured C2C12
cells were trypsinized, washed once with PBS, resus-
pended in OptiMEM (Invitrogen, USA) plus 0.1% FBS
and seeded in 96-well plates at 15,000 cells per 80 μL per
well. Immediately after seeding, cells were transfected with
the -1147Id1-luciferase plasmid [35], a Smad1 expression
plasmid and a beta-galactosidase expression plasmid using
Fugene6 (Promega, USA) according to the manufacturer’s
instruction. After 24 hours of growth, 10 μL of series di-
luted ligands in OptiMEM medium were added into the
cell culture in triplication. After 16 hours of treatment,
the cells were washed once with PBS and lysed for meas-
uring luciferase and beta-galactosidase activities using a
Mithras LB 940 microplate reader (Berthold Technologies,
Germany). The luciferase activity in each well was normal-
ized with the beta-galactosidase activity, and the data were
analyzed by using Prism 5 software (GraphPad Software,
Inc., USA). The CHO-derived hBMP-9 was purchased
from R&D Systems (Minneapolis, USA). The E. coli-de-
rived hBMP-2 was purchased from joint Protein Central
(http://www.jointproteincentral.com, Incheon, Korea).
Surface plasmon resonance analysis
The proteins of the extracellular domain (ECD) of Type
I and Type II receptors were purchased from R&D Sys-
tems (Minneapolis, USA) as C-terminal Fc-tagged chi-
meras. The binding affinities between MB109 and the
ECDs were measured using a BIAcore 3000 (GE Health-
care, USA) at 25°C following a protocol described
previously with minor modification [18,26]. In brief, the
ECD-Fc proteins were prepared in a pH 4.0 solution
(10 mM Na-acetate, pH 4.0) and were captured on the
flow cell 2, 3 and 4 of the CM5 sensor chip at a flow rate
of 10 μL/min until the density reached ~1,000 response
units. Flow cell 1 was left blank for background subtrac-
tion. For kinetic analysis, purified MB109 was pre-
pared in a series of 2-fold dilution, from 20 to 0.3
nM, in an assay solution (10 mM HEPES, pH 7.4,
150 mM NaCl, 3.4 mM EDTA and 0.005% Tween-20)
and injected over the flow cells at a flow rate of
50 μL/ml. All tests were performed using the set of
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The data fitting was performed using a minimum of five
protein concentrations and a global 1:1 Langmuir binding
with mass transfer model.
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